Novo Nordisk’s Summer Crossroads: Medicare Tailwinds, Pill Boom, and a Pivotal FDA Verdict
26.06.2026 - 22:46:27 | boerse-global.de
The oral version of Wegovy has racked up more than three million prescriptions since its US launch in January 2026, and now a new demand driver is about to kick in. From July 1, Medicare will cover the weight-loss drug, with eligible seniors paying roughly $50 a month. Analysts estimate that around 10% of Medicare members could qualify for the benefit, potentially opening a vast new patient pool. The tablet already accounts for about 60% of Novo Nordisk’s new US prescriptions, and nearly 80% of those users are first-timers to GLP-1 therapy rather than patients switching from the injectable version.
Yet the same US market that is fuelling this surge is also applying intense pricing pressure. Novo Nordisk has already announced it will cut the list prices of Wegovy and Ozempic in the US starting January 2027. One major pharmacy benefit manager has signalled it will favour Eli Lilly’s competing drugs going forward, putting future revenue at risk. The patent on semaglutide is also expiring in China, a market that contributes roughly 6.5% of group sales, opening the door for local copycats that will squeeze margins.
The battle for the next generation of obesity treatments is intensifying. Eli Lilly’s experimental drug retatrutide has shown weight loss of up to 28.7% in phase 3 studies, while its oral pill Foundayo is also generating high prescription volumes. Novo Nordisk is pinning its hopes on CagriSema, which delivered a 22.7% mean weight reduction after 68 weeks in the REDEFINE-1 trial. After 84 weeks that figure edged up to 23%, but Lilly’s tirzepatide achieved 25.5% in comparable studies — a key threshold the market had been watching. The US Food and Drug Administration is expected to rule on CagriSema in the fourth quarter, and investors view that decision as the most important catalyst for the stock this year.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Beyond obesity, the company is also advancing its haematology pipeline. At the ISTH congress in Paris (July 11–15), Novo Nordisk will present new clinical data from the FRONTIER4 study of denecimig (Mim8) for haemophilia A, as well as first results from the Explorer10 trial of concizumab for children with haemophilia A or B with inhibitors. A US approval application for denecimig has already been submitted to the FDA.
To keep up with soaring demand for its GLP-1 products, Novo Nordisk has been ramping up production capacity. A new plant in the Czech Republic came online in June 2026, and additional facilities in Ireland and France are scheduled to be completed by 2028. Regulatory issues at its filling plant in Indiana, however, remain unresolved.
The stock closed on Friday at €42.00, roughly 11% above its 50-day moving average but still 31% below its 52-week high of €61.20. The relative strength index sits at 70.7, suggesting short-term overbought conditions. The management’s full-year forecast calls for a currency-adjusted revenue decline of 5% to 13% and an operating profit drop of 4% to 12%.
The next major checkpoints are closely watched. Second-quarter results are due on August 5, with analysts focusing particularly on patient retention rates for the oral Wegovy. Higher-dose adherence is critical to building durable revenue. That will be followed by the FDA’s decision on CagriSema — a ruling that could either cement the stock’s recovery or leave it vulnerable to another leg down just as pricing headwinds intensify. For Novo Nordisk, the balance between volume growth in international markets and falling prices in the US is becoming the defining equation of 2026.
Ad
Novo Nordisk Stock: New Analysis - 26 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
